Investigator of Nexalin's Brazilian Trial Wins Young Researcher Award for DIFS™ Platform
NXL sits 18% above its 52-week low of $0.305 on light trading volume (0.1× avg).
Summary
An investigator for Nexalin's Brazilian clinical trial received the Young Researcher Award at BRAIN 2026 for research evaluating the company's DIFS™ platform, which demonstrated significant improvement in sleep quality for patients with anxiety and insomnia. This award follows the announcement of compelling clinical trial results from the same Brazilian study on June 10, 2026. Nexalin already holds ANVISA approval in Brazil for its SYNC medical device. This independent scientific recognition enhances the credibility and visibility of Nexalin's technology, which is crucial as the company prepares for its product launch in the Brazilian market. Watch for the upcoming product launch in Brazil.
At the time of this announcement, NXL was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $0.31 to $2.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.